Constellation Pharmaceuticals, Inc. CNST
Day range unavailable
52-week range unavailable
- Market cap
- 1.63B
- Shares out
- 47.97M
- Forward P/E
- -8.83
- Beta
- 2.58
- Analysts
- Hold
- Price target
- 40.71 (+19.8%)
- Earnings date
- Aug 4, 2021
Key statistics
- Enterprise value
- 1.25B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -70.84M
- Total cash
- 382.08M
- Total debt
- 3.37M
- Return on equity
- -40.70%
- Short % of float
- 7.01%
- 50-day average
- 33.82
- 200-day average
- 28.33
Analyst view
Consensus: hold
- Target (low)
- 34.00
- Target (mean)
- 40.71
- Target (high)
- 75.00
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 4, 2021
Expected Aug 4, 2021. Consensus EPS estimate -0.88.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 4, 2021 | Jun 1, 2021 | -0.89 | — | — | — |
| May 10, 2021 | Mar 1, 2021 | -0.80 | — | — | — |
| Feb 24, 2021 | Dec 1, 2020 | -0.74 | — | — | — |
| Oct 29, 2020 | Sep 1, 2020 | -0.71 | — | — | — |
| Aug 5, 2020 | Jun 1, 2020 | -0.64 | — | — | — |
| May 6, 2020 | Mar 1, 2020 | -0.64 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 17, 2021 | RBC Capital | down | Outperform | Sector Perform |
| Jun 4, 2021 | Jefferies | down | Buy | Hold |
| Jun 3, 2021 | Truist Securities | down | Buy | Hold |
| Jun 3, 2021 | Cowen & Co. | down | Outperform | Market Perform |
| Jan 25, 2021 | BMO Capital | up | Market Perform | Outperform |
| Sep 8, 2020 | Oppenheimer | down | Outperform | Perform |
About Constellation Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- constellationpharma.com
News
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology 
Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib 
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Constellation Pharmaceuticals, Inc. - CNST 
Why Constellation Pharmaceuticals Stock Was Crushing It This Week 
66 Biggest Movers From Yesterday 
SHAREHOLDER ALERT: WeissLaw LLP Investigates Constellation Pharmaceuticals, Inc. 
Why Constellation Pharmaceuticals Stock Is Skyrocketing Today 
40 Stocks Moving In Wednesday's Mid-Day Session 
Shareholder Alert: Ademi LLP investigates whether Constellation Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with MorphoSys 
Constellation Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Constellation Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CNST
Your note
Sign in to keep a note on CNST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AUDIA JAMES E | Director | Sale | May 11, 2020 | 25,434 |
| COLUMN GROUP L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 16, 2021 | 0 |
| EVNIN ANTHONY B | Director | Purchase | Dec 12, 2019 | 0 |
| GOLDSMITH MARK A | Director | Conversion of Exercise of derivative security | Mar 3, 2021 | 89,857 |
| RAYTHATHA JIGAR | Officer and Director | Sale | May 11, 2020 | 14,961 |
| REEVE EMMA | Chief Financial Officer | Sale | Feb 21, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wellington Management Group, LLP | 9.19% | 4,404,129 | 103.01M | Mar 30, 2021 |
| VR Adviser, LLC | 8.38% | 4,016,873 | 93.95M | Mar 30, 2021 |
| Avoro Capital Advisors LLC | 6.16% | 2,950,000 | 69.00M | Mar 30, 2021 |
| Blackrock Inc. | 5.53% | 2,649,702 | 61.98M | Mar 30, 2021 |
| Column Group LLC | 5.48% | 2,626,631 | 61.44M | Mar 30, 2021 |
| RA Capital Management, L.P. | 4.67% | 2,238,536 | 52.36M | Mar 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 3.48% | 1,667,798 | 33.04M | May 30, 2021 |
| Vanguard Explorer Fund, Inc. | 2.15% | 1,028,762 | 22.24M | Apr 29, 2021 |
| Victory Portfolios-Victory RS Small Cap Growth Fund | 1.74% | 834,100 | 19.51M | Mar 30, 2021 |
| Vanguard Total Stock Market Index Fund | 1.69% | 809,284 | 18.93M | Mar 30, 2021 |
| iShares Russell 2000 ETF | 1.53% | 731,760 | 14.50M | May 30, 2021 |
| PGIM Jennison Health Sciences Fd | 0.97% | 464,338 | 9.20M | May 30, 2021 |